Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.9983 -0.1417 (-1.74%) Market Cap: 2.24 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.29 GF Score: 35/100

Iovance Biotherapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 03:00PM GMT
Release Date Price: $7.89 (-1.38%)
Michael Yee
Iovance Biotherapeutics, Inc. - Analyst

Good morning, everyone. Thank you for joining us on another great session here at the Jefferies Healthcare Conference. I'm Michael Yee, senior biotechnology analyst at Jefferies. And very happy to have on the stage with us members of the Iovance management team, Interim CEO, Fred Vogt, as well as the COO, Igor Bilinsky. Importantly, they're joining us now at a time when the BLA was recently accepted by the FDA with the priority review. And I believe there's a PDUFA date. as well, formally for November. and with no planned AdCom. So should be straightaway steady sailing towards an approval.

And maybe that would be a good start to offer Fred an opportunity to maybe talk a little bit about the journey this year, right, now that the BLA is on file. How you're feeling about this year, both from a regulatory review standpoint and preparing for approval and commercialization of this new melanoma drug?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot